GCG and macrothrombocytopenia and granulocyte inclusions with or without nephritis or sensorineural hearing loss: As a result, a DPP-4-resistant GLP-2 analog (teduglutide) has been used in the treatment of short bowel syndrome (SBS) since 2012 (Jeppesen et al., 2018).